MedPath

The Effect of Atomoxetine on Cognitive Symptoms in Schizophrenia Patients

Phase 3
Recruiting
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT20211219053452N1
Lead Sponsor
Arak University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Schizophrenia
Get a score of 61 or higher on the panss questionnaire

Exclusion Criteria

Simultaneous presence of other neurological disorders
Any allergy to atomoxetine
Patients who have received ECT in the last 6 weeks

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Wechsler Short-Term Memory Test. Timepoint: Before the intervention and after 8 weeks of treatment. Method of measurement: Wechsler test.
Secondary Outcome Measures
NameTimeMethod
Short-term memory expansive score, direct visual memory, reverse visual memory, direct auditory memory, auditory reverse memory. Timepoint: Before the intervention and after 8 weeks of treatment. Method of measurement: How to measure short-term memory, direct visual memory, reverse visual memory, direct auditory memory, auditory reverse memory using Wechsler test.
© Copyright 2025. All Rights Reserved by MedPath